百济神州的医保猜想:领先外企一个身位,还有必要谈吗?

健识局
27 Jun

一年一度的医保谈判,到了哨声最紧张的阶段。各家都攒着劲想搭上新药获批的“末班车”。乳腺癌、非小细胞肺癌等多个领域挤满了玩家,最有话题度的,还要数胆道癌领域。5月29日,百济神州HER2靶点的重磅新药泽尼达妥单抗正式获批上市,用于治疗既往接受过全身治疗的HER2高表达不可切除局部晚期或转移性胆道癌患者。HER2靶点出了名的“卷”,临床布局就从单抗向多抗体转变、适应症更是越多越好,就连大外企也不得不...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10